trans-3-hexenoyl raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-22. Anything still debated is marked as such rather than presented as settled.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Bayer's original trade name of heroin is typically used in non-medical settings. It is used as a recreational drug for the euphoria it induces. Anthropologist Michael Agar once described heroin as "the perfect whatever drug." Tolerance develops quickly, and increased doses are needed in order to achieve the same effects. Its popularity with recreational drug users, compared to morphine, reportedly stems from its perceived different effects. Short-term addiction studies by the same researchers demonstrated that tolerance to heroin and morphine developed at a similar rate. When compared to the opioids hydromorphone, fentanyl, oxycodone, and pethidine (meperidine), former addicts showed a strong preference for heroin and morphine, suggesting that heroin and morphine are particularly susceptible to misuse and causing dependence. Morphine and heroin were also much more likely to produce euphoria and other positive subjective effects when compared to these other opioids. Heroin came into widespread use in South Africa in 2009 but the epidemic of heroin addiction has escalated since 2013 as prices have fallen rapidly in recent years. Heroin is primarily used by unemployed young men. Heroin generates intense feelings of euphoria, deep contentment, and relaxation. It also reduces appetite. Effects may last two to four hours. The drug can be inhaled after being warmed in a glass pipe but can be also smoked with cannabis in the form of a joint. It is primarily injected intravenously.
== Biography == Born on 27 September 1958 in the Indian state of Maharashtra, K. V. Subba Rao graduated in science from the University of Pune and before starting his career by joining Malti-Chem Research Centre, Baroda, he secured his master's degree also from the same university in 1979. Subsequently, he did his doctoral studies under Sukhdev at Maharaja Sayajirao University of Baroda and moved to Johns Hopkins University in 1983 for his post-doctoral studies at their Division of Environmental Chemistry where he worked with Miles R. Chedekel. After working for two years there, he joined the laboratory of Fred C. Fox at the University of California and worked there for three more years. Returning to India in 1988, he joined the International Centre for Genetic Engineering and Biotechnology where he held different positions as that of a research scientist (1988–91) and research assistant (1991–94) and was the Group Leader of the Immunology Group (1994-2015).
This is relevant for enzymes like pepsin that are active in acidic environments such as the mammalian stomach and lysosomes, but does not significantly apply to intracellular enzymes. In highly basic conditions (pH greater than 10, not normally seen in physiological conditions), the ammonio group is deprotonated to give NH2−CHR−CO−2. Although various definitions of acids and bases are used in chemistry, the only one that is useful for chemistry in aqueous solution is that of Brønsted: an acid is a species that can donate a proton to another species, and a base is one that can accept a proton. This criterion is used to label the groups in the above illustration. The carboxylate side chains of aspartate and glutamate residues are the principal Brønsted bases in proteins. Likewise, lysine, tyrosine and cysteine will typically act as a Brønsted acid. Histidine under these conditions can act both as a Brønsted acid and a base.
Sources: en.wikipedia.org
== Proton-coupled amino acid transporters 1 and 2 == The molecular weight of Proton-coupled amino acid transporter 1 is 53.28 kDA; the molecular weight of Proton-coupled amino acid transporter 2 is 53.22 kDA. PAT1 has been found in lysosomes in brain neurons but also in the apical membrane of intestinal epithelial cells where it is associated with the brush border. Proton-coupled amino acid transporter 1 has a higher affinity for proline than it does for glycine and alanine Proton-coupled amino acid transporter 2 is found subcellularly in the kidneys, lungs, spinal cord, and brain and likely has a role in myelinating neurons. It has an overall higher affinity for glycine, alanine, and proline than PAT1 but is more specific for what can inhibit it.
In physical chemistry and fluid mechanics, a non-Newtonian fluid is a fluid that does not follow Newton's law of viscosity; that is, it has variable viscosity dependent on stress. In particular, the viscosity of non-Newtonian fluids can change when subjected to force. Ketchup, for example, becomes runnier when shaken and is thus a non-Newtonian fluid. Many salt solutions and molten polymers are non-Newtonian fluids, as are many commonly found substances such as custard, toothpaste, starch suspensions, paint, blood, melted butter and shampoo. A common demonstration of non-Newtonian fluids involves so-called "Ooblek" (), a mixture of corn or potato starch and water. It demonstrates shear thickening. With slow motions it is a moderately viscous fluid, increases in viscosity as disturbed, and briefly transforms into a near solid mass upon a sudden impact. Most commonly, the viscosity (the gradual deformation by shear or tensile stresses) of non-Newtonian fluids is dependent on shear rate or shear rate history. Some non-Newtonian fluids with shear-independent viscosity, however, still exhibit normal stress-differences or other non-Newtonian behavior. In a Newtonian fluid, the relation between the shear stress and the shear rate is linear, passing through the origin, the constant of proportionality being the coefficient of viscosity. In a non-Newtonian fluid, the relation between the shear stress and the shear rate is different. The fluid can even exhibit time-dependent viscosity. Therefore, a constant coefficient of viscosity cannot be defined.
== Match records == Highest score: 32.16 (208) v Footscray 9.8 (62) – Round 22, 1982, at Western Oval Lowest score: 0.9 (9) v Fitzroy 6.11 (47) – Round 1, 1899, at Brunswick Street Oval Lowest score since 1919: 1.12 (18) v St Kilda 5.5 (35) – Round 10, 1923, at Junction Oval Highest losing score: Essendon 21.13 (139) v Collingwood 23.6 (144), Round 22, 1987, M.C.G. Lowest winning score: Essendon 1.8 (14) v Melbourne 0.8 (8), Finals Week 3, 1897, Lake Oval (League record) Lowest winning score since 1919: Essendon 3.10 (28) v Footscray 3.5 (23), Round 13, 1989, Windy Hill Greatest winning margin: 165 points – Essendon 28.16 (184) v South Melbourne 2.7 (19), Round 18, 1964, Windy Hill Greatest losing margin: 163 points – Essendon 11.7 (73) v Sydney Swans 36.20 (236), Round 17, 1987, S.C.G. Record attendance (home-and-away game): 94,825 – 25 April 1995 at MCG v Collingwood (inaugural Anzac Day match) Record attendance (finals match): 116,828 – 1968 VFL Grand Final v Carlton
Sources: en.wikipedia.org
== Production == To produce cheese, rennet or an edible acid is added to heated milk. This makes the milk coagulate or curdle (heat-acid coagulation), separating the milk solids (curds) from the liquid whey. Sweet whey is the byproduct of rennet-coagulated cheese, and acid whey (also called sour whey) is the byproduct of acid-coagulated cheese. Sweet whey has a pH greater than or equal to 5.6; acid whey has a pH less than or equal to 5.1. Whey can also be made by adding an acid such as cream of tartar to milk and warming it, letting the curds settle to the bottom.
Expense must also be duly considered with such assays as they become more frequently applied in very large studies (e.g. potentially involving thousands of samples). While other approaches are also being made commercially available (e.g. iterative mapping of peptides, fluorescent variation of Edman degradation, and nanopores) these (i) remain broadly untested outside the firms involved; (ii) yield largely, if not completely, only proteogenomic data; (iii) are thus, currently at least, quite limited in terms of any capacity for a broad assessment of proteoforms; (iv) are dependent on the quality of the affinity or other (multiple) reagents required which; (v) tends to also increase costs per assay to the consumer. Notably, while promising, nanopore sequencing is (i) still quite early in development; and (ii) remains unproven in terms of throughput and capacity to address the full range of known PTM and adducts. Thus, the capacity for nanopores to quantitatively address the full breadth of a proteome remains untested. Other technical issues such as potential clogging of pores will also need to be addressed with hopefully routine solutions.
Tissue-type plasminogen activator, short name tPA, is a protein that facilitates the breakdown of blood clots. It acts as an enzyme to convert plasminogen into its active form plasmin, the major enzyme responsible for clot breakdown. It is a serine protease (EC 3.4.21.68) found on endothelial cells lining the blood vessels. Human tPA is encoded by the PLAT gene, and has a molecular weight of ~70 kDa in the single-chain form. tPA can be manufactured using recombinant biotechnology techniques, producing types of recombinant tissue plasminogen activator (rtPA) such as alteplase, reteplase, and tenecteplase. These drugs are used in clinical medicine to treat embolic or thrombotic stroke, but they are contraindicated and dangerous in cases of hemorrhagic stroke and head trauma. The antidote for tPA in case of toxicity is aminocaproic acid.
(i.e. the deviatoric stress in a Newtonian fluid has no normal stress components), and it has a compressibility term in addition to the incompressible case, which is proportional to the shear viscosity:
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.